Is avatrombopag the imported drug with the best platelet-raising effect?

Among the imported drugs for the treatment of thrombocytopenia, Avatrombopag has received widespread attention in recent years and is considered to be one of the TPO receptor agonists with a significant platelet-raising effect and high safety. However, whether it is the "best effect" needs to be comprehensively evaluated based on clinical indications, individual patient response, drug characteristics, and the performance of alternative drugs such as Eltrombopag, Lusutrombopag and Hetrombopag.

Avatrombopag is an oral small moleculeTPO-R agonist, which can effectively simulate the effect of thrombopoietin (TPO), stimulate the differentiation and maturation of bone marrow megakaryocytes, and thereby promote platelet production. The drug has been approved by the US FDA and the European EMA. It is mainly suitable for patients with chronic immune thrombocytopenia (ITP) and chronic liver disease to use it to increase platelet count in the short term before performing operations with a risk of bleeding. Its advantage is that it is not affected by food after oral administration, does not require hepatic enzyme inducers to adjust the dose, and has shown a stable dose-response relationship and good tolerance in multiple clinical trials. Compared with eltrombopag, an important feature of avitrombopag is that it does not significantly interact with polyvalent cations in the diet (such as calcium and magnesium), making it more convenient for patients to take the medication, and there is no need to take the medication frequently on an empty stomach or pay attention to dietary restrictions.

Eltrombopag is one of the earliest widely usedTPO-R agonists. It also has rich clinical data and usage experience, and is suitable for various indications such as ITP, hepatitis C-related thrombocytopenia, and severe aplastic anemia. Although the efficacy is accurate, its interaction with food, especially high-calcium diet, affects the absorption efficiency, making the administration method relatively cumbersome and requiring it to be taken on an empty stomach. At the same time, side effects such as liver function damage and changes in serum iron have been observed in some patients, and liver enzymes and iron metabolism indicators need to be regularly monitored.

Rutrombopag is mainly used for thrombocytopenia related to liver disease. It has a faster response in increasing platelet velocity and usually takes effect 7 to 10 days after taking it. However, its indications are relatively narrow and are limited to optimized platelet management before surgery, and are not suitable for long-term maintenance use.

Hetrombopag is a new generation of TPO agonist independently developed in China It has been gradually promoted in the domestic market in recent years. It has good bioavailability and platelet-raising ability, and its price is also more advantageous. It is especially suitable for patients in some areas covered by medical insurance. However, its international data and long-term safety observations are still relatively limited, and its use as a broad indication is still in the stage of gradual promotion.

From a comparison of efficacy, avatrombopag is equivalent to or even slightly superior to eltrombopag in terms of short-term platelet-raising effect, with better control of side effects and higher medication compliance. For patients who need a short-term rapid increase in platelets to complete surgery or interventional treatment, avatrombopag provides a more balanced choice between efficacy and safety. In ITP patients, avatrombopag can significantly increase platelet count within 2-3 weeks, and some patients can even reach normal levels, and the rebound is small after stopping the drug. However, whether it is suitable for long-term maintenance still depends on the patient's specific condition.

Reference materials:https://go.drugbank.com/drugs/DB11995